Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST

Rebecca Kotzur, Natan Stein, Shira Kahlon, Orit Berhani, Batya Isaacson, Ofer Mandelboim*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Natural killer (NK) cells are currently used in clinical trials to treat tumors. However, such therapies still suffer from problems such as donor variability, reproducibility, and more, which prevent a wider use of NK cells therapeutics. Here we show a potential immunotherapy combining NK cell-mediated tumor eradiation and long non-coding (lnc) RNAs. We overexpressed the interferon (IFN) γ secretion-enhancing lncRNA nettoie Salmonella pas Theiler's (NeST) in the NK cell-like cell line YTS. YTS cells express the co-stimulatory receptor 2B4 whose main ligand is CD48. On YTS cells, 2B4 functions by direct activation. We showed that NeST overexpression in YTS cells resulted in increased IFNγ release upon interaction with CD48 (selectively enhanced (se)YTS cells). Following irradiation, the seYTS cells lost proliferation capacity but were still able to maintain their killing and IFNγ secretion capacities. Finally, we demonstrated that irradiated seYTS inhibit tumor growth in vivo. Thus, we propose seYTS cells as off-the-shelve therapy for CD48-expressing tumors.

Original languageAmerican English
Article number107284
Issue number8
StatePublished - 18 Aug 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors


  • Cancer
  • Cellular therapy
  • Components of the immune system


Dive into the research topics of 'Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST'. Together they form a unique fingerprint.

Cite this